Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results

Highlights include:

Fourth Quarter 2025

• Reported revenues were $434.9 million, representing a decrease of 1.7% on a reported basis and 2.5% on an organic basis compared to the fourth quarter of 2024.
• GAAP earnings per diluted share were $(0.02), compared to $0.25 in the fourth quarter of 2024.
• Adjusted earnings per diluted share were $0.83, compared to $0.97 in the fourth quarter of 2024.

Full-Year 2025

• Reported revenues were $1,635.2 million, representing an increase of 1.5% on a reported basis and a decrease of 0.7% on an organic basis compared to full-year 2024.
• GAAP earnings per diluted share were $(6.74), compared to $(0.09) in 2024.
• Adjusted earnings per diluted share were $2.23, compared to $2.56 in 2024.

“In the fourth quarter, we drove tangible operational progress while continuing to deliver for our customers and patients,” said Mojdeh Poul, president and chief executive officer. “During 2025, we further strengthened our quality management system, advanced our Compliance Master Plan, and progressed execution of our remediation work. Our operational and execution focus resulted in significant outcomes in key areas, namely Integra Skin supply reliability, healthier safety stock levels across our portfolio, and early relaunch of PriMatrix and Durepair.”

Click here for the full press release.